AMX-168

N/A

Report date: 2026/03/19 16:58:14

Base Information

Drug NameAMX-168

Drug Alias Nametumor-associated-protease-activated anti-CD3/anti-EpCAM bispecific T-cell engager prodrug (Amunix)AMX-168

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsEpithelial cell adhesion molecule modulators

TargetsT cell surface glycoprotein CD3Epithelial cell adhesion molecule

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAmunix Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAmunix Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A